Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business UpdateGlobeNewsWire • 08/13/25
CYCLACEL PHARMACEUTICALS HIGHLIGHTS PRECLINICAL DATA SHOWING THAT CANCER OF THE BILIARY TRACT IS SENSITIVE TO PLOGOSERTIBGlobeNewsWire • 08/04/25
CYCLACEL PHARMACEUTICALS HIGHLIGHTS PUBLICATION OF PRECLINICAL DATA SHOWING THAT PLOGOSERTIB IS ACTIVE IN A HARD-TO-TREAT SUBTYPE OF LIVER CANCERGlobeNewsWire • 07/07/25
Cyclacel Pharmaceuticals Announces $3 Million Private Placement Offering of Convertible Preferred StockGlobeNewsWire • 06/20/25
CYCLACEL PHARMACEUTICALS REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENTGlobeNewsWire • 06/03/25
CYCLACEL PHARMACEUTICALS REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATEGlobeNewsWire • 05/15/25
CYCLACEL PHARMACEUTICALS, INC. ANNOUNCES EXECUTION OF SHARE EXCHANGE AGREEMENT TO MAKE FITTERS SDN.GlobeNewsWire • 05/06/25
Cyclacel Pharmaceuticals Reports Fourth Quarter Financial Results and Provides Business UpdateGlobeNewsWire • 04/02/25
Cyclacel Pharmaceuticals Announces $1 Million Private Placement Offering of Convertible Preferred StockGlobeNewsWire • 03/24/25
Cyclacel Pharmaceuticals Announces Closing of a Change of Control Transaction and Appointment of New Executive LeadershipGlobeNewsWire • 02/27/25
Cyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David LazarGlobeNewsWire • 01/03/25
Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating CostsGlobeNewsWire • 12/05/24
Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross ProceedsGlobeNewsWire • 11/14/24
Cyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross ProceedsGlobeNewsWire • 11/13/24
Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business UpdateGlobeNewsWire • 11/12/24
Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard RuleGlobeNewsWire • 10/24/24
Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR SymposiumGlobeNewsWire • 10/23/24
Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR SymposiumGlobeNewsWire • 10/09/24
Cyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched Patient Cohort of Its Phase 2 StudyGlobeNewsWire • 09/25/24
Cyclacel Pharmaceuticals Announces Participation at the H.C. Wainwright 26th Annual Global Investment ConferenceGlobeNewsWire • 09/04/24